Agents of transmissible spongiform encephalopathies (TSEs) usually enter the body via a peripheral route and replicate in lymphoreticular tissues before moving into the brain. Any impairment of the ...
Dr Haumschild continues leading a discussion surrounding management of PNH, emphasizing the impact of complement inhibitors. Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights ...
With Alzheimer’s disease therapies finally reaching the market and hundreds of active clinical trials for therapies and diagnostics, it seems like every week brings another potential avenue to explore ...
AJMC ®: How has treatment of complement-driven diseases changed since 2007, when the first complement inhibitor, eculizumab, was approved? SMITH: The development of eculizumab followed our ...
A recent article posted to the medRxiv* preprint server discussed the role of complement factor H-related protein 5 (CFHR5) in venous thromboembolism (VTE) patients and hospitalized coronavirus ...
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume ...
Complement 3 glomerulopathy (C3G) is a rare kidney disease that affects your body’s innate immune system (complement system). Complement 3 glomerulopathy (C3G) is a kidney disease that’s caused by ...
Please provide your email address to receive an email when new articles are posted on . Meningococcal vaccination rates are low among eligible patients with complement component deficiencies, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results